drugset / Trial / NCT01276262

Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects

NCT01276262

Phase 1 Completed 22 enrolled AstraZeneca
Non-randomizedCrossoverSingle-blindBasic science

Summary

A crossover study to assess the effect of repeated doses of fostamatinib on the levels of oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib. The study will also evaluate the safety and tolerability of fostamatinib in combination with an oral contraceptive

Timeline

Start
2011-03
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostamatinib Small molecule 100 mg Oral
Subject Microgynon 30® Unknown Oral

Indications

No indication recorded.